Aligos Therapeutics Inc. (ALGS) NASDAQ
$1.25 0.06 (5.04%)
Market Cap: $53.37M
As of 05/27/22 04:00 PM EDT. Market closed.
Aligos Therapeutics Inc. (ALGS) NASDAQ
$1.25 0.06 (5.04%)
Market Cap: $53.37M
As of 05/27/22 04:00 PM EDT. Market closed.
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted ... read more
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Aligos is focused on the discovery and development of targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses as well as leveraging its expertise in liver diseases to create targeted therapeutics for nonalcoholic steatohepatitis (NASH). Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver disease, particularly viral hepatitis, to rapidly advance its pipeline of potentially best-in-class molecules. read less
Open in:
Open in:
| Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
| Novo Holdings A/S | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 2,614,563 | Oct 22, 2020, 04:31 PM |
| Woiwode Thomas | Director | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 862,444 | Oct 20, 2020, 05:00 PM |
| Vivo Capital VIII, LLC | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 483,267 | 7,249,005 | 3,116,658 | Oct 20, 2020, 04:59 PM |
| Vivo Capital VIII, LLC | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 66,733 | 1,000,995 | 430,372 | Oct 20, 2020, 04:59 PM |
| Versant Venture Capital VI, L.P. | 10% Owner | Oct 20, 2020 | Buy | $15.00 | 200,000 | 3,000,000 | 862,444 | Oct 20, 2020, 04:58 PM |
| Owner | Relationship | Date | Value($) |
| Novo Holdings A/S | 10% Owner | 10/20/2020 | 3,000,000 |
| Woiwode Thomas | Director | 10/20/2020 | 3,000,000 |
| Vivo Capital VIII, LLC | 10% Owner | 10/20/2020 | 7,249,005 |
| Vivo Capital VIII, LLC | 10% Owner | 10/20/2020 | 1,000,995 |
| Versant Venture Capital VI, L.P. | 10% Owner | 10/20/2020 | 3,000,000 |
Period of Report: 03/31/2022
10-K/10-Q Filings: View